Moreover, combining cGAMP with anti-MSLN CAR-NK-92 cells could enhance pancreatic cancer cells’ cytotoxicity and anti-tumor activity, potentially forming a unique clinical treatment approach. This evidence concerns the gene MSLN and neoplasm.